Introduction {#s1}
============

Intercellular communication mediated by extracellular vesicles (EVs) has recently attracted significant attention, and may contribute to diverse physiological processes including immune regulation and cancer metastasis. EVs are comprised of two major classes based upon their mechanism of biogenesis: microvesicles are shed directly from the plasma membrane, while exosomes are formed by intra-lumenal budding during multi-vesicular endosome (MVE) biogenesis ([@bib9]; [@bib51]) ([Figure 1A](#fig1){ref-type="fig"}). EVs contain a wide range of molecules, including antigens, signaling proteins, lipids, and microRNAs (miRNAs) that appear to induce significant biological changes in recipient cells. EV miRNAs released by both tumor and mesenchymal cells are of particular interest, as they may play important roles in metastasis ([@bib4]). EV miRNAs secreted by hypothalamic stem cells may regulate aging in mice ([@bib58]). Moreover, EVs have attracted a great deal of attention due to their potential use in diagnostics and therapeutics ([@bib4]). Despite their importance, how miRNAs are specifically packaged and released via the EV pathway is poorly understood. The biological significance of EVs also remains controversial, in part due to a lack of understanding of the molecular mechanisms that regulate their formation and release. Here we describe the development of a novel CRISPR screening platform using artificially barcoded miRNAs (bEXOmiRs) that we applied systematically to identify genes involved in EV biology. We show that EV release is regulated tightly by Glycogen Synthase Kinase three and Wnt signaling, and report new players in MVE exocytosis.

![Development and assessment of bEXOmiRs as high-throughput reporters of EV release.\
(**A**) Left, Generic structure of bEXOmiRs before and after processing. bEXOmiRs contain a random 15 nucleotide (nt) (base-paired) sequence followed by a constant exosome-targeting motif (GGAGGAG, 'EXO motif'). Middle, intracellular trafficking of bEXOmiRs before export via EVs (exosomes and/or microvesicles). Once secreted, bEXOmiRs can be detected in purified EV fractions by RT-PCR or next generation sequencing. (**B**) Three example bEXOmiRs (**A, B, C**; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) were cloned into a mammalian expression vector and transfected into HEK293T cells. bEXOmiR expression in both EV (upper panel) and cellular (bottom panel) fractions was assessed by Stem-Loop RT-PCR. Negative control RT-PCR devoid of RT-primer is shown in lane ∅. Red asterisks indicate non-specific PCR amplification bands. (**C**) HEK293T cells transfected with control or RAB27A siRNA. Fresh media was added 24 hr post-transfection; EVs were then isolated 48 hr later. Semi-quantitative RT-PCR gel images (top) show relative levels of a bEXOmiR reporter in both cellular (Cells) and EV fractions from control and RAB27A siRNA-treated cells from two experiments. Graph shows bEXOmiR level after RAB27A depletion, as quantified by qRT-PCR (n = two independent experiments, EXP\#1 and EXP\#2). Immunoblots at bottom show depletion of RAB27A; α-Tubulin was a loading control. Marker mobility is shown at left in basepairs (**B** and **C**) top panels) or kilodaltons (**C** bottom panels). (**D**) Reproducibility of 5000 bEXOmiR abundances measured by deep sequencing in isolated EVs from two replicate cultures (REP1 and REP2) of K562 cells previously infected with the 5,000-bEXOmiR test library (see text).](elife-41460-fig1){#fig1}

Results and discussion {#s2}
======================

bEXOmiRs as reporters of EV release {#s2-1}
-----------------------------------

To create a high-throughput system that monitors EV release by next generation sequencing in a pooled format, we first designed and engineered artificially barcoded, exosomal microRNAs (bEXOmiRs) that could be expressed, targeted and released from cells in EVs ([Figure 1A](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). bEXOmiRs were designed based upon miR-30 to include a 15 nucleotide (nt) barcode within the paired, stem sequences, flanked by EV-targeting (GGAGGAG 'EXO motif') and loop sequences derived from miR-601 that were reported by Sanchez Madrid and colleagues to enhance miRNA exosomal targeting ([@bib54]) ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Barcode sequences were designed to retain the base pairing characteristics of endogenous miRNA stem regions. After intracellular processing, mature bEXOmiRs would be expected to contain the 15 nt barcode followed by GGAGGAG (22 nt total).

Upon expression of a few trial lentiviruses encoding a bEXOmiR downstream of a GFP open-reading frame in HEK293T cells, bEXOmiR RNAs were detected in EV fractions by RT-PCR, together with established EV protein markers ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B--D](#fig1s1){ref-type="fig"}). The EV-associated, amplified bEXOmiR sequences were derived from an RNA source since control reactions lacking either the first-strand cDNA synthesis primer or reverse transcriptase failed to yield a product ([Figure 1---figure supplement 1C,D](#fig1s1){ref-type="fig"}). bEXOmiRs in isolated EVs were protected significantly from RNase digestion only in the absence of nonionic detergent, and they floated in a sucrose density gradient ([Figure 1---figure supplement 1D and E](#fig1s1){ref-type="fig"}), consistent with their being membrane-enclosed. The remaining, RNase-resistant bEXOmiRs are likely to be protected by RNA binding proteins. Moreover, treatment with Bafilomycin A1, which enhances EV release ([@bib14]; [@bib29]), greatly increased the abundance of both total EV protein markers and bEXOmiR reporters in isolated EV fractions ([Figure 1---figure supplement 1F,G](#fig1s1){ref-type="fig"}). bEXOmiR expression did not change the number or size of CD63-positive structures in K562 cells ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Finally, consistent with previous reports ([@bib33]), Rab27A depletion resulted in a \~ 50% reduction of a bEXOmiR reporter in these fractions from HEK293T cells ([Figure 1C](#fig1){ref-type="fig"}, and see below for K562 cells). Thus, bEXOmiRs can be expressed, processed and exported from cells in EVs using previously characterized pathways.

Next, we designed an initial test library comprised of 5000 different bEXOmiRs. The original bEXOmiR design included miR-30 context sequences flanking the hairpin structure ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Processing of these sequences in miR-30 relies on a structural bulge created by a single base pair mismatch at the base of the hairpin ([Figure 1---figure supplement 1H](#fig1s1){ref-type="fig"}). Although our original design did not include this feature, no significant differences were observed in the EV representation of bEXOmiRs with or without the A-C mismatch; we nevertheless retained this motif to be consistent with previous artificial shRNA designs ([@bib7]). Comparison of bEXOmiR abundance in two replicate EV analyses showed excellent concordance (R^2^ = 0.95; [Figure 1D](#fig1){ref-type="fig"}); this was also true when comparing two independent or replicate screens as described below (see below Figure 3A, B).

The overall representation of bEXOmiRs in EV fractions suggested that intrinsic differences in barcode sequences to some extent, influenced exosomal targeting, as seen for other miRNAs ([@bib54]; [@bib42]; [@bib49]). Some bEXOmiRs were very efficiently detected in EVs while others were not ([Figure 1D](#fig1){ref-type="fig"}). This does not reflect differences in synthesis, because a comparison of EV and cellular bEXOmiR levels showed very poor correlation with probability of release (see Figure 3 C below). An initial search for sorting motifs within barcode sequences using the MEME algorithm ([@bib3]) was unsuccessful. Despite the limitation of some preferential targeting of individual barcodes, these data demonstrate that bEXOmiRs are suitable reporters for high-throughput monitoring of EV release in a pooled format. In addition, certain RNA sequences dominated the sequencing analyses, compromising sequencing depth. Such bEXOmiR outliers were excluded from subsequent screens, and we also size fractionated RNAs and introduced a hairpin oligonucleotide in our sequencing library preparation to remove a major contaminant that dominated sequencing runs. These measures improved the overall sequencing depth significantly enough to permit us to complete a genome-wide screen using suspension grown cell cultures.

A CRISPR/Cas9 screen using bEXOmiRs {#s2-2}
-----------------------------------

We next used bEXOmiRs in a pooled, genome-wide CRISPR/Cas9-mediated screening protocol to monitor EV release ([Figure 2A](#fig2){ref-type="fig"}). Briefly, unique CRISPR single guide (sg)RNAs linked by synthesis with distinct bEXOmiRs were co-expressed; we then determined how knockout of every gene influenced EV release by comparing bEXOmiR barcode abundance in EV fractions isolated from wild type compared with Cas9-edited cells ([Figure 2A](#fig2){ref-type="fig"}). Our hope was that the use of 10 CRISPR sgRNAs per gene, coupled with 10 different barcodes (one per sgRNA) would overcome any limitation of any individual bEXOmiR barcode EV packaging bias, relative efficiencies of different sgRNAs at disrupting gene function, or the real possibility that an sgRNA would decrease a particular bEXOmiR's abundance. In this scenario, gene deletions that decrease extracellular bEXOmiR abundance are considered activators of EV production in WT conditions; in contrast, deletions that increase extracellular bEXOmiR abundance are considered as suppressors of this process.

![Genome-wide CRISPR/Cas9 screen using bEXOmiRs enables systematic interrogation of EV biology.\
(**A**) Diagram depicting key steps of the screen performed in this study. Oligonucleotides encoding sgRNA-bEXOmiR pairs were designed computationally and then synthesized using solid-phase technology. Next, oligonucleotides were pool-cloned (1) into a Lentivirus vector that drives expression of both sgRNA and bEXOmiR under U6 and EF1α promoters, respectively. WT and Cas9-positive K562 cells were then infected at low MOI (2), such that after infection and selection, each cell expresses only a single sgRNA-bEXOmiR pair (3). This approach enables identification and quantification of both EVs and their respective cell of origin via unique molecular identifiers: barcodes and sgRNAs respectively. sgRNA-bEXOmiR-expressing cells were then grown for 48 hr before collection of culture supernatants from which EVs were purified (4). Finally, barcode abundance was measured, comparing WT and Cas9-expressing cells, by deep sequencing from EV-extracted RNA ([@bib54]). (**B**), Initial pilot screen using a 25,000 bEXOmiR-sgRNA library targeting membrane trafficking, mitochondrial and motility (MMM) genes. Colored insets display zoomed activator (red nodes in red inset) and suppressor (blue nodes in blue inset) hits that passed effect size cutoffs (≤ −2 or ≥+2) and had a -Log p-value\>1.5. (**C**), genome-wide (minus MMM sublibrary) screen. Colored insets display zoomed activator and suppressor hits that passed effect size cutoffs (≤ −2 or ≥+2) and had a -Log p-value\>2.5. Green labels in (**B**) and (**C**) indicate previously known EV regulators; yellow labels represent genes that regulate miRNA trafficking or processing.](elife-41460-fig2){#fig2}

Two initial, independent pilot screens targeted \~2300 membrane trafficking, motility and mitochondria-related (MMM) genes, including known EV release-regulators, (eg. SMPD3, RAB27A, MCOLN3, YKT6, etc.) as positive controls and \~200 negative control sgRNAs. As expected, analysis of barcode abundance in EVs isolated from large-scale cultures revealed a gene signature consistent with previous studies ([@bib9]; [@bib51]; [@bib29]; [@bib33]; [@bib22]; [@bib23]; [@bib28]; [@bib18]) ([Figure 2B](#fig2){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Among the top hits identified in both initial, independent screens were two known activators: neutral sphingomyelinase (SMPD3), which has been shown to regulate EV-mediated miRNA export ([@bib22]; [@bib23]; [@bib6]), and mucolipin-3 (MCOLN3), an endolysosomal Ca^2+^ channel important for MVE exocytosis ([@bib29]). Additionally, YKT6, a v-SNARE that regulates EV release was identified as a suppressor, as previously reported ([@bib9]; [@bib18]). Although endocytosis of EVs by surface proteins might lead to a decrease in EV bEXOmiR abundance, we did not detect a large cluster of endocytosis genes in our screen.

To achieve genome-wide coverage, we performed parallel replicate screens using eight additional sub-libraries ([Figure 2C](#fig2){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Additional known players, including SYT7 and three ESCRT-associated genes (ALIX, HRS and MVB12B) were also confirmed. Interestingly, knockout of any ESCRT-related component consistently increased bEXOmiR abundance in EVs, while knockout of SMPD3 had the opposite phenotype, as previously reported in assays monitoring release of endogenous miRNAs ([@bib22]). This may reflect distinct EV release pathways. It is also critical to note that knockout of key components specific to one route may artificially increase flux through the other pathway.

Altogether, this analysis (nine duplicated sub-library screens) required \>100 liters of cell culture supernatants for EV preparations and associated, large-scale miRNA sequencing runs. [Figure 3A,B](#fig3){ref-type="fig"} shows a comparison of total bEXOmiR abundance in EV analyses from two replicate screens that similar to our test bEXOmiR ([Figure 1D](#fig1){ref-type="fig"}), also showed excellent concordance (R^2^ = 0.95). Shown in [Figure 3C](#fig3){ref-type="fig"} is a comparison of total bEXOmiR abundance in cells versus EVs. There was essentially no correlation between these pools (R^2^ = 0.13--0.17), consistent with differential sorting of bEXOmiRs into EVs, as observed for endogenous miRNAs. Note that we have not sorted our hits based on EV enrichment in the present analysis. Importantly, comparative analysis of the relative growth of all bEXOmiR expressing cells (determined by genomic sgRNA sequencing) compared with the ability of a given sgRNA to enhance or repress EV levels, revealed no correlation between growth and EV release phenotype ([Figure 3D,E](#fig3){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}) which would have yielded a diagonal line.

![Analysis of bEXOmiR EV-targeting.\
Reproducibility of \~32,000 bEXOmiR abundances measured in EVs isolated from replicated WT- (**A**) or Cas9-positive (**B**) cell cultures (REP\#1 and \#2). (**C**) Correlation of \~32,000 bEXOmiR abundances in EVs versus intact cells (Cells) from the same WT replicated cultures (left, REP\#1; right, REP\#2) shown in (**A**). (**D**) Correlation of growth versus EV phenotypes observed in the genome-wide screen. (**E**) Correlation of growth versus EV phenotypic scores calculated using the casTLE algorithm (see Materials and methods) in the genome-wide analysis. Red and blue dots represent identified activator or suppressor hits from the EV generation screen, respectively.](elife-41460-fig3){#fig3}

Functional network analysis identified clusters of genes that both positively and negatively regulate specific cellular processes related to EV biogenesis and release, as well as miRNA processing and trafficking ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). For example, XPO5 and the RAN GTPase activating protein, RANGAP1 gene products regulate miRNA shuttling from the nucleus to the cytoplasm ([@bib55]; [@bib12]), and would be expected to be important for bEXOmiR release. Specific clusters identified include genes needed for regulation of miRNA processing and activity, actin dynamics, Wnt related signaling and trafficking, and ribosome biogenesis ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). GPCR-related proteins including histamine H3 receptor were also identified ([Figure 2C](#fig2){ref-type="fig"}, [Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Histamine and neurotransmitter-mediated GPCR signaling have recently been shown to regulate EV release ([@bib53]; [@bib17]). Actin dynamics has also been implicated in the process by which EVs are released from cells ([@bib25]; [@bib20]; [@bib44]), and of particular interest in this context was the requirement for ARHGEF18, a guanine nucleotide exchange factor for Rho GTPases ([@bib56]). ARHGEF18 regulates actin dynamics in multiple contexts ([@bib46]; [@bib47]; [@bib2]) including invadopodia formation ([@bib2]), a process recently proposed to promote EV release ([@bib20]; [@bib44]).

![Functional network analysis of top hits.\
Only genes (nodes) that showed interactions in STRING analyses or that fell into a related functional category (gene clusters) are displayed. Interactions reported by STRING are represented by gray edges whose width is proportional to a combined significance score (see Materials and methods). Activators are shown in red, suppressors in blue. Node color intensity is proportional to the effect size found in the screen. Node size is proportional to significance score (-Log *p*-value) calculated in the screen analysis. In all panels, asterisks indicate that an isoform or close family member has been shown to play a role in the same category.](elife-41460-fig4){#fig4}

A number of RNA binding proteins (RBPs) have recently been shown to target miRNAs into EVs, including YBX1, hnRNPA2B1 and SYNCRIP ([@bib54]; [@bib42]; [@bib39]). Although several RNA-binding proteins were uncovered here (i.e. NHP2L1 or LONP1, [Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), as well as miRNA-binding proteins XPO5 and PCDC11 ([@bib49]) ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), we did not find any previously described EV-related RNA binding proteins. This may either be due to their roles in packaging miRNAs that are distinct from the artificial miRNAs to which they were linked in this screen, or to cell type-specific differences ([@bib54]; [@bib42]; [@bib39]).

As mentioned earlier, bEXOmiRs showed significant differences in their efficiency of being detected in EV fractions ([Figure 1D](#fig1){ref-type="fig"}, [Figure 3A,B](#fig3){ref-type="fig"}). To explore the impact of such heterogeneity on overall screen outcomes, we tested the ability of different bEXOmiRs to function when paired with the same individual sgRNAs used to target the 100 top hits identified in our initial MMM screen ([Figure 2B](#fig2){ref-type="fig"}, [Figure 5---figure supplement 2A,B](#fig5s2){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Although some differences were observed in terms of our ability to detect various players in screens run with different bEXOmiRs/gRNA pairs, we were nevertheless able to re-confirm the findings obtained in the initial screen. Unexpectedly, YKT6, which appeared as a suppressor in the initial screen ([Figure 2B](#fig2){ref-type="fig"}), was uncovered as a slight activator instead; this may be related to differences in the bEXOmiRs associated with this gene in the two separate analyses. Indeed, YKT6 appears to be required for EV-dependent Wnt release along with STX1A ([@bib9]; [@bib18]), a close homologue of STX1B ([Figure 2B](#fig2){ref-type="fig"}). It is important to note that the phenotype observed relies on the efficiencies of both sgRNAs and their paired, bEXOmiRs: some guides work better than others, and the same applies for bEXOmiRs. This limitation highlights the importance of orthogonal hit-validation experiments. Usually 2--3 guide-bEXOmiR associations supported each hit, and in most cases more than 90% of bEXOmiRs were recovered upon EV fraction sequencing ([Supplementary file 2](#supp2){ref-type="supplementary-material"}).

Hit validation {#s2-3}
--------------

The importance of ARHGEF18 in EV biogenesis was confirmed using an orthogonal, Nanostring method to profile the presence of 74 endogenous miRNAs in EVs produced by polyclonal human K562 cell lines subjected to CRISPR knockout of either SMPD3 or ARHGEF18 genes ([Figure 5A](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). In both cases, upon knockout of these gene products, the abundance of most miRNAs decreased \~50% in EVs but not the corresponding cellular fractions. For the miRNAs that increased significantly upon hit knockout, about half of these were seen in both replicates ([Figure 5A](#fig5){ref-type="fig"}). qPCR analysis of two of these endogenous miRNAs confirmed miRNA export decreases in cells depleted of SMPD3, RHOV, ARHGEF18, and BAIAP3 ([Figure 5---figure supplement 1A--D,J](#fig5s1){ref-type="fig"}). In addition, orthogonal protein assays comparing protein abundance in cellular versus EV fractions confirmed roles for SMPD3, RHOV, ARHGEF18, BAIAP3, PPP1R1C, and TREM1 in EV formation ([Figure 5](#fig5){ref-type="fig"}, B and C, [Figure 5---figure supplement 1A--F](#fig5s1){ref-type="fig"}). Knockout of PPP1R14D and NKD2 suppressors of bEXOmiR release yielded somewhat more variable results between experiments ([Figure 5](#fig5){ref-type="fig"}, B and C, [Figure 5---figure supplement 1G,H](#fig5s1){ref-type="fig"}).

![Validation of selected hits with orthogonal assays.\
(**A**), Quantitative Nanostring miRNA profiling of both cellular (Cells) and EV fractions was performed to compare endogenous miRNA signatures in SMPD3 CRISPR knockout (KO) or ARHGEF18 KO K562 cell lines versus control cells; blue and green violin plots, respectively. miRNA abundance is plotted as percent of miRNA abundance in control cells. Violin plots show overall distribution of common EV-associated miRNAs (circles) detected in two independent experiments. Three specific endogenous miRNAs, hsa-miR-19a-3p (black), hsa-miR-151a-3p (red) and hsa-miR-548b-3p (blue) are indicated. (**B**) and (**C**), Biochemical analysis of EV fractions in CRISPR knockout cell lines from selected hits derived from the initial MMM-focused (**B**) or from the rest of the genome-wide (**C**) screen. EV extracts were immunoblotted with anti-HSC70, anti-Flotillin or anti-CD81 antibodies; numbers at left indicate mobility of molecular weight markers in kD. Bars indicate standard deviation from two independent sets of two replicate experiments. (**D**) Fusion of pHluorin-CD63-positive structures at the surface of HeLa cells observed using TIRF microscopy of fluorescent siRNA-transfected cells. Each dot represents number of events per cell over 90 s. (**E**) and (**F**), Characterization of purified EVs by Nanoparticle Tracking Analysis (NTA). (**E**) Representative plot of EV size distribution. Black line and red-shaded areas indicate mean value and SEM of particle concentration at each diameter, respectively, determined after three measurements. (**F**) Yield comparison of EVs derived from control and CRISPR knockout (KO) cells.](elife-41460-fig5){#fig5}

Two different regulatory subunits of protein-phosphatase 1 (PP1), PPP1R1C and PPP1R14D, were detected as either activator or suppressor hits in our screen; both of these phenotypes were validated by immunoblot analysis of knockout cell lines ([Figure 5C](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1E,H](#fig5s1){ref-type="fig"}). PP1 has been shown to play roles in yeast vacuolar fusion events as well as in exocytosis in mammalian cells ([@bib10]; [@bib35]; [@bib43]; [@bib16]), consistent with a link to EV biogenesis regulation; moreover, the regulatory subunits are important for substrate selectivity and thus may reflect complementary phosphatase reactions.

New players in MVE exocytosis {#s2-4}
-----------------------------

In an attempt to determine more precisely, the pathway(s) impacted by several of the key hits identified, we made use of a TIRF microscopy-based live cell assay to monitor MVE exocytosis specifically, in real time, visualized using a stably expressed, pHluorin-based CD63 reporter ([@bib53]) in HeLa cells transfected with fluorescent siRNAs ([Video 1](#video1){ref-type="video"}). In this assay. CD63 fluorescence is only detected upon delivery to the cell surface where the protein encounters a neutral pH. As expected, RAB27A-depleted cells showed \~50% reduction in MVE exocytosis, recorded by TIRF microscopy ([Figure 5D](#fig5){ref-type="fig"}). In agreement with our findings ([Figure 5A--C](#fig5){ref-type="fig"}), siRNA-depletion of RHOV, ARHGEF18, BAIAP3, or PPP1R1C also decreased MVE exocytosis ([Figure 5D](#fig5){ref-type="fig"}; [Figure 5---figure supplement 1, K,L](#fig5s1){ref-type="fig"}; [Videos 1](#video1){ref-type="video"} and [2](#video2){ref-type="video"}). Thus, these genes appear to regulate CD63-positive MVE exocytosis. Nanoparticle tracking analysis (NTA) of isolated EV fractions from corresponding CRISPR knock-out cell lines further confirmed a role for these genes in the release of EV particles ([Figure 5E,F](#fig5){ref-type="fig"}), the size of which peaked between 100--150 nm ([Figure 5E](#fig5){ref-type="fig"}). Our isolation method yielded a narrow distribution of particle sizes, and only the absolute number of particles changed upon knock out of the indicated genes ([Figure 5F](#fig5){ref-type="fig"}). Moreover, there was no visually apparent change in the overall abundance or size of CD63-positive compartments in the cells analyzed, except for cells depleted of BAIAP3, which showed an accumulation of CD63-containing structures in the vicinity of filopodia-like structures ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Together, these data suggest strongly that a block in MVE exocytosis explains the decrease in EV numbers detected for cells depleted of RHOV, ARHGEF18, BAIAP3, and PPP1R1C.

###### Time-lapse of a control HeLa cell stably expressing pHluorin-CD63 at 3.3X real time speed shown as a heat map.

Images were acquired at three frames per sec.

10.7554/eLife.41460.013

###### Time-lapse of an ARHGEF18 KD HeLa cell stably expressing pHluorin-CD63 at 3.3X real time speed as in [Video 1](#video1){ref-type="video"}.

10.7554/eLife.41460.014

Wnt signaling in EV biology {#s2-5}
---------------------------

Wnts are growth stimulatory factors and critical developmental regulators that are also implicated in a variety of cancers ([@bib32]). Wnts are palmitoylated in the secretory pathway and may themselves be carried to neighboring cell targets on the surface of EVs ([@bib32]). Canonical Wnt signaling requires binding to the seven transmembrane spanning, Frizzled receptor and LRP co-receptors, to trigger a pathway that leads to the translocation of β-Catenin to the nucleus where it serves as a transcriptional co-activator ([@bib32]). A number of Wnt-signaling modulators appeared among the hits as EV biogenesis regulators ([Figure 4](#fig4){ref-type="fig"}). These include LYPD6B, a relative of LYPD6 that interacts with Frizzled and LRP6 and enhances Wnt signaling ([@bib34]), as well as the ubiquitin ligase RNF146 that activates Wnt signaling by ubiquitinating Axins ([@bib57]). Knockout of these components decreased EV recovery, suggesting that Wnt signaling enhances EV release under the conditions of cell growth used in our screen. This conclusion is consistent with our discovery that loss of NKD2, a negative regulator of Wnt signaling, also enhanced bEXOmiR release in the screen ([Figure 4](#fig4){ref-type="fig"}; [Figure 5B](#fig5){ref-type="fig"}).

DeRobertis and colleagues showed previously that Wnt signaling involves intralumenal targeting of the Wnt receptor complex and associated Glycogen Synthase Kinase 3 (GSK3) and Axin into multivesicular endosomes (MVEs), in a process that requires HRS and VPS4 (*37*); this process inhibited GSK3 to enable stabilization of β-Catenin. Thus, components needed for EV release may also regulate invagination of GSK3 and Axin into MVEs. Indeed, GSK3 regulates endolysosome biogenesis via MITF, TFEB and TFE3 transcription factors ([@bib37]).

Wnt stimulation was shown previously to activate ARHGEF18 ([@bib50]) and to up-regulate RHOV expression ([@bib15]), both validated activator hits in this screen. Other genes identified here include two regulatory subunits of PP1, which showed opposite roles in EV release regulation. PP1 is a downstream modulator in both GPCR and Wnt signaling pathways. EV release is controlled by PKC-mediated SNAP23 phosphorylation, the closest homologue of SNAP25 ([@bib1]), which mediates exocytosis upon PP1-mediated hydrolysis of PKC-phosphorylated residues ([@bib16]).

To explore further the role of canonical Wnt signaling in EV generation, the effect of Wnt3a addition on EV release was tested in K562 cells ([Figure 6A](#fig6){ref-type="fig"}). Paradoxically, addition of Wnt3a to overnight serum starved cells decreased the appearance of EV markers LAMP1, HSC70 and CD81, all of which were rescued upon addition of DKK1 protein that inhibits Wnt signaling by binding to the Wnt co-receptor, LRP6 (*34*). Consistent with these findings, the GSK3 inhibitor, CHIR99021 that activates the Wnt pathway led to a significant decrease in EV levels from K562 and HEK293T cells ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Finally, LiCl was also employed as a less specific activator of Wnt signaling and also led to a decrease in EV generation ([Figure 6---figure supplement 1B,C](#fig6s1){ref-type="fig"}).

![Wnt signaling regulates EV release.\
(**A**) Serum-starved K562 cells were treated with PBS (control) or Wnt3a (100 ng/ml) or Wnt3a + Dickkopf peptide (DKK1, 200 ng/ml) for 24 hr prior to EV isolation. Biochemical analysis of cellular (Cells) and EV fractions was performed by immunoblotting of extracts using antibodies against antigens shown. Detection of ß-Catenin was carried out using cytosolic fractions. (**B**) Quantitation of EV marker protein levels from EV immunoblots shown in (**A**). (**C**), Serum-starved K562 cells were treated with DMSO (control) or CHIR99021 (10 µM) for 24 hr prior to EV isolation. Biochemical analysis of EV fractions was performed as in (**A**). Representative immunoblots for a control experiment along with two replicate CHIR99021-treated samples are shown. (**D**) Quantitation of protein levels from EV immunoblots in (**C**). (**E**) Quantitation of LAMP1 protein from cellular fractions in (**C**). Molecular mass marker mobility is shown at the left of immunoblot panels in kilodaltons. *t* test: \*p\<0.05; \*\*p\<0.01; error bars represent SEM; *n* ≥ 3. (**F**) Flow cytometry determination of LAMP1 levels in anti-LAMP antibody-labeled control and CHIR99021-treated cells. Confocal images at right show lysosomes stained with anti-LAMP1 antibody (green) and nuclei labeled with DAPI (blue). Bar,10 µm.](elife-41460-fig6){#fig6}

Inhibition of GSK3 by CHIR99021 increased LAMP1 protein levels as determined by immunoblot ([Figure 6E](#fig6){ref-type="fig"}) and flow cytometry ([Figure 6F](#fig6){ref-type="fig"}), and was accompanied by an increase in lysosome numbers ([Figure 6F](#fig6){ref-type="fig"}); this would be expected, as Wnt-mediated GSK3 inhibition stabilizes the key endo-lysosomal transcriptional regulators, MITF and TFE transcription factors ([@bib37]; [@bib36]) that also regulate MVE exocytosis ([@bib27]). Accordingly, mRNA levels of the endo-lysosomal genes, LAMP1 and MCOLN1 increased upon CHIR99021 treatment ([Figure 7A](#fig7){ref-type="fig"}). As expected, a robust, concomitant upregulation of AXIN2 was also observed.

![GSK3 inhibition decreases Rab27 mRNA levels.\
(**A**) qPCR analysis of indicated mRNA levels in K562 cells treated for 20 hr with CHIR99021. Shown is the combined data from four independent experiments; error bars represent SEM (*t* test: \*p\<0.05; \*\*p\<0.01). (**B**) Immunoblot of RAB27 levels in duplicate samples treated with CHIR99021 as in A. (**C**) Schematic representation of the pathway by which Wnt regulates exosome release. The link between RAB27 and GSK3 is not yet known.](elife-41460-fig7){#fig7}

Previous studies have shown that in melanosome-producing cells, RAB27A gene expression is positively regulated by MITF/TFE transcription factors ([@bib8]). According to this scenario, stabilization of these transcriptional regulators upon GSK3 inhibition would be expected to upregulate RAB27 ([@bib36]). Surprisingly, we observed \~50% reduction of RAB27A mRNA levels upon GSK3 inhibition in K562 cells under the conditions employed ([Figure 7A](#fig7){ref-type="fig"}); this was accompanied by a corresponding decrease in RAB27A protein levels ([Figure 7B](#fig7){ref-type="fig"}). These data likely explain the reduction of EV release observed upon CHIR99021 treatment, and suggest that in K562 cells, GSK3 influences RAB27 transcription in an unexpected way ([Figure 7C](#fig7){ref-type="fig"}).

It is important to note that in our hands, melanosome-producing RPE cells behaved differently than K562 cells upon CHIR99021 treatment: they displayed increased EV production and did not show a decrease in RAB27A protein ([Figure 6---figure supplement 1D](#fig6s1){ref-type="fig"}). Altogether, these findings indicate that cell type-specific effects ([@bib19]) contribute to differences in GSK3-mediated EV generation and highlight the complexity of Wnt-mediated signaling and GSK3 regulation in cells.

Why did our screen indicate that Wnt is an activator rather than a suppressor of EV release? The validation experiments were done under starvation conditions to maximize the signal---this will have additional impacts on endo-lysosomal gene regulation by TFEB and MITF regulators. How RAB27 gene expression is regulated upon GSK3 inhibition will be interesting to investigate in the future.

Although K562 cells have been reported to express both Wnts and Frizzled receptors ([@bib40]), we did not see a significant change in EV levels upon blocking Wnt secretion with the Wnt palmitoylation inhibitor (C59) in our parental cell cultures. This suggests that under the conditions of the screen (but not the conditions of the validation testing), knockout of various components reflected protein roles that are independent of Wnt signaling processes. Most importantly, when we tested EV release in wild type parental cells, we detected a very strong role for the GSK3 kinase in EV release regulation. Indeed, Bafilomycin A1 treatment, that activates EV release, actually inhibits Wnt signaling ([@bib11]). It is very satisfying that the very EV pathway that may generate functional Wnt signals ([@bib32]) is in fact directly regulated by Wnt signaling via an important and yet to be characterized feedback mechanism. Altogether, complex crosstalk between signaling pathways may influence EV secretion in ways that will be important to define in future work.

Conclusion {#s2-6}
----------

Despite recent advances in EV research, how EV generation is regulated at the molecular level is poorly understood. We have used artificially barcoded miRNAs as surrogate reporters of EV release to enable genome-wide dissection of EV biology. We validated a number of previously reported players and discovered many new ones, including a gene cluster devoted to cortical actin dynamics and a role for ARHGEF18 in MVE exocytosis of EV-associated miRNAs. Wnt signaling- and trafficking-related genes were also prominently represented in the functional network analysis; we found that Wnt-mediated inactivation of GSK3 tightly regulates EV release by down-regulating RAB27 mRNA and protein levels. Collectively, EV biogenesis and release appear to be part of a complex feedback mechanism that regulates Wnt signaling in cells. Finally, our screen also uncovered genes involved in intracellular trafficking and processing of miRNAs. Indeed, bEXOmiR technology can also be leveraged to study miRNA biogenesis, processing and binding to RNA-binding proteins. This genome-wide screen has provided significant leads to aid in our understanding of the molecular basis of EV generation and regulation in cells and tissues.

Materials and methods {#s3}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                      Designation                          Source or\                               Identifiers                                                                   Additional\
  (species) or resource                                                   reference                                                                                                              information
  ---------------------------------- ------------------------------------ ---------------------------------------- ----------------------------------------------------------------------------- ------------------------
  Cell line (*Homo sapiens*)         K562                                 ATCC                                     RRID: [CVCL_0004](https://scicrunch.org/resolver/CVCL_0004)                   

  Cell line (*Homo sapiens*)         K562 Cas9+                           PMID: 27018887                                                                                                         

  Cell line (*Homo sapiens*)         K562 ARHGEF18 KO \#5                 this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 ARHGEF18 KO \#7                 this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 BAIAP3 KO \#8                   this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 NKD2 KO \#3                     this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 PPP1R1C KO \#4                  this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 PPP1R14D KO \#1                 this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 RAB27A KO \#1                   this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 RHOV KO \#10                    this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 SMPD3 KO \#9                    this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         K562 TREM1 KO \#9                    this paper                                                                                                             Progenitor: K562 Cas9+

  Cell line (*Homo sapiens*)         HEK293T                              <https://mrcppureagents.dundee.ac.uk/>   RRID: [CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)                   

  Cell line (*Homo sapiens*)         HeLa                                 ATCC                                     RRID: [CVCL_0030](https://scicrunch.org/resolver/CVCL_0030)                   

  Antibody                           mouse monoclonal anti-a-Tubulin      Sigma-Aldrich                            T5168                                                                         (1:10000)

  Antibody                           rabbit polyclonal anti-ARHGEF18      GeneTex                                  GTX102223; RRID: [AB_10728594](https://scicrunch.org/resolver/AB_10728594)    (1:1000)

  Antibody                           rabbit polyclonal anti-Rab27A        Synaptic Systems                         168 013                                                                       (1:1000)

  Antibody                           mouse monoclonal anti-CD81           BD Biosciences                           555675                                                                        (1:1000)

  Antibody                           mouse monoclonal anti-ß-Catenin      BD Biosciences                           562505; RRID: [AB_11154224](https://scicrunch.org/resolver/AB_11154224)       (1:1000)

  Antibody                           mouse monoclonal anti-Golgin 97      Thermo Scientific                        A-21270                                                                       (1:1000)

  Antibody                           rabbit polyclonal anti-Flotillin-1   Novus Biologicals                        NBP1-79022; RRID: [AB_11011337](https://scicrunch.org/resolver/AB_11011337)   (1:1000)

  Antibody                           mouse polyclonal anti-Calnexin       Santa Cruz                               sc-23954                                                                      (1:1000)

  Antibody                           mouse monoclonal anti-HSC70          Santa Cruz                               sc-7298                                                                       (1:1000)

  Antibody                           mouse monoclonal anti-LAMP1          DSHB                                     G1/139/5; RRID: [AB_10659721](https://scicrunch.org/resolver/AB_10659721)     (1:2)

  Antibody                           mouse monoclonal anti-CD63           DSHB                                     H5C6; RRID: [AB_528158](https://scicrunch.org/resolver/AB_528158)             (1:1000)

  Antibody                           rabbit polyclonal anti-GDIß          PMID: 8195183                            home-made                                                                     (1:1000)

  Antibody                           mouse monoclonal\                    EMD Millipore                            MABT837                                                                       (1:1000)
                                     anti-LBPA                                                                                                                                                   

  Genetic reagent\                   ARHGEF18 (siRNA)                     Dharmacon                                                                                                              
  (*Homo sapiens*)                                                                                                                                                                               

  Genetic reagent(*Homo sapiens*)    BAIAP3 (siRNA)                       Dharmacon                                                                                                              

  Genetic reagent(*Homo sapiens*)    RHOV (siRNA)                         Dharmacon                                                                                                              

  Genetic reagent(*Homo sapiens*)    PPP1R1C (siRNA)                      Dharmacon                                                                                                              

  Genetic reagent (*Homo sapiens*)   RAB27A (siRNA)                       Dharmacon                                                                                                              

  Recombinant DNA reagent            pMCB306                              PMID: 28319085                                                                                                         

  Recombinant DNA reagent            pMCB306-pHluorin-CD63                this paper                                                                                                             Progenitor: pMCB306

  Chemical compound, drug            Recombinant Mouse Wnt-3a Protein     R and D Sysytems                         1324-WN-002                                                                   

  Chemical compound, drug            CHIR-99021                           Selleckchem                              S1263                                                                         

  Chemical compound, drug            DharmaFECT 1                         Dharmacon                                                                                                              

  Chemical compound, drug            Bafilomycin-A1                       Sigma-Aldrich                                                                                                          

  Software, algorithm                Fiji                                                                          RRID: [SCR_002285](https://scicrunch.org/resolver/SCR_002285)                 

  Software, algorithm                CellProfiler                         PMID: 17076895                           RRID: [SCR_007358](https://scicrunch.org/resolver/SCR_007358)                 

  Other                              DAPI                                 Invitrogen                               RRID: [AB_2307445](https://scicrunch.org/resolver/AB_2307445)                 1:10000
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture, antibodies and immunofluorescence\--HEK293T cells were grown in Dulbecco\'s modified Eagle\'s media (DMEM) containing 10% fetal bovine serum, 2 mM L-glutamine, and penicillin (100 U/ml)/streptomycin (100 μg/ml). Wild type (WT) and Cas9-expressing ([@bib31]) K562 cells were grown in RPMI 1640 Medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and penicillin (100 U/ml)/streptomycin (100 μg/ml). All cell lines were cultured at 37°C with 5% CO~2~; cells were routinely tested for Mycoplasma using either a MycoAlert Mycoplasma Detection kit (Lonza LT07-318) or PCR. Their identity was assumed to be determined by ATCC. Extracellular vesicle-free media was prepared by overnight ultracentrifugation of RPMI supplemented with 20% FBS at 100,000 X g in a 45Ti rotor, as described ([@bib48]).

Transfections of HEK293T cells plated in 10 cm dishes were carried out using 1.5 μg of bEXOmiR-encoding plasmid DNA (pEGFP-bEXOmiR) mixed with 1 ml serum-free DMEM and 30 μL polyethylenimine (PEI, 1 mg/ml, pH 7.0, PolySciences Inc.) and incubated at room temperature for 30 min. The mixture was added to cells that were grown for 48 hr before EV isolation. For Bafilomycin-A1 (Sigma-Aldrich) treatment, the drug was added to cell media at 10 nM and cells were cultured for 20 hr before EV collection.

Mouse monoclonal anti-α-Tubulin was from Sigma-Aldrich, rabbit polyclonal anti-ARHGEF18 was from GeneTex and anti-Rab27A was from Synaptic Systems. Mouse monoclonal anti-CD81, anti-β-Catenin and anti-Golgin 97 were from BD biosciences. Polyclonal anti-GDIβ was previously described ([@bib13]). Rabbit polyclonal anti-Flotillin-1 antibody was from Novus Biologicals (NBP1-79022). Polyclonal anti-Calnexin and monoclonal anti-HSC70 antibodies were from Santa Cruz. Mouse monoclonal anti-LAMP1 antibody culture supernatant was from Developmental Studies Hybridoma Bank (University of Iowa, Iowa city, IA). Mouse monoclonal anti-LBPA and anti-CD63 antibodies were from EMD Millipore (MABT837) and DHSB (H5C6), respectively.

Immunofluorescence\-- HeLa cells were transfected with fluorescently labeled siRNAs (DY547 label; Dharmacon) using DharmaFECT one transfection reagent, cultured for 48 hr, and replated on glass coverslips. To visualize K562 cells, cells were attached to glass coverslips using cytospin (Shandon) at 800 rpm for 5 min. Cells were then fixed with 3.7% (v/v) paraformaldehyde for 15 min, washed and permeabilized/blocked with 0.1% saponin/1% BSA-PBS before staining with anti-LAMP1 antibody followed by goat anti-rabbit Alexa 488 (1:2,000). Nuclei were stained using 0.1 µg/ml DAPI (Sigma-Aldrich). Coverslips were mounted on glass slides with Mowiol and imaged using a spinning disk confocal microscope (Yokogawa) with an electron multiplying charge-coupled device (EMCCD) camera (Andor, UK) and a 100 × 1.4 NA oil immersion objective. Finally, unbiased quantification of CD63-positive vesicles was performed using CellProfiler software ([@bib5]).

Immunoblotting\--HEK293T or K562 cells were harvested after 24--48 hr and lysed in lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM MgCl2, and 1% Triton X-100) supplemented with protease inhibitors. After centrifugation at 12,000 g for 10 min, protein concentrations were measured in the cleared lysates. Equal amounts were resolved by SDS-PAGE followed by immunoblot analysis. EV final pellets were resuspended in SDS-PAGE loading dye (50 mM Tris-HCl pH 6.8, 6% glycerol, 2% SDS, 0.2% bromophenol blue), heated briefly at 95°C and resolved by 10% SDS-PAGE. After transfer to nitrocellulose and antibody incubation, blots were detected with ECL western blotting detection substrate or visualized using LI-COR Odyssey Imaging System. Isolation of cytosolic fractions from cell post-nuclear supernatants was performed as described ([@bib26]). For optimal detection of EV fraction markers (such as CD81), no reducing agent was added to the SDS-PAGE loading dye. Immunoblot signals visualized using LI-COR were analysed using ImageJ and presented as average ±SEM.

EV isolation\--K562 suspension cell cultures were seeded at 5 × 10^5^ cells/ml in EV-free RPMI and grown for 24--48 hr. Cell cultures were centrifuged at 300 × g, 5 min to pellet cells, and supernatants were centrifuged again at 2100 × g, 20 min to pellet dead cells. The resulting supernatant was spun again at 10,000 × g, 30 min to pellet cell debris and large apoptotic bodies; for large scale screen cultures this step was replaced by filtration through 0.45 µm filter units (Thermo Scientific). After this, filtration through 0.22 µm filter units (Thermo Scientific) was performed. Filtered media were ultracentrifuged for 70 min at 100,000 × g in 45Ti rotor to pellet extracellular vesicles. The supernatant was discarded and the pellet re-suspended in phosphate-buffered saline (PBS) and centrifuged again for 70 min at 100,000 × *g* in TLA100.2 rotor. Discontinuous sucrose gradient flotation was as described ([@bib42]). EV pellets were frozen in liquid nitrogen and stored at −80 ˚C prior to further processing.

Nanoparticle tracking analysis\--EVs were purified from control and CRISPR KO K562 polyclonal cell cultures as described (see EV isolation). After final ultracentrifugation, pelleted EVs were resuspended in PBS and analyzed on a NanoSight NS300 (Malvern Panalytical) using a sCMOS camera. Three, 60 s 25 Hz movies were taken per sample. Data were analyzed using NTA 3.1 software (Malvern Panalytical).

Flow cytometry analysis of LAMP1\--K562 cells were treated with either DMSO or CHIR99021. After 24 h cells were harvested and washed before fixation in 2% paraformaldehyde, permeabilization and staining with anti-LAMP1 and Alexa Fluor 488 goat anti--mouse antibodies (Invitrogen). Quantification of LAMP1 total fluorescence was performed using a BD Accuri C6 flow cytometer and data were analyzed using Flowjo software (Tree Star).

Total internal reflection fluorescence (TIRF) microscopy\--HeLa cells stably expressing pHluorin-CD63 were transfected with fluorescently labeled siRNAs (DY547 label; Dharmacon) using DharmaFECT one transfection reagent, cultured for 48 hr, and replated on chambered coverglass (Thermo Scientific). After 24 hr, cells containing fluorescent siRNAs were imaged on an inverted microscope (Nikon Eclipse Ti) equipped with an electron-multiplying charge-coupled device camera (ANDOR iXon^EM^+), an Apo TIRF 100X/1.49 oil DIC objective, and Nikon Perfect Focus System. Time lapse videos were acquired at 3 Hz with Nikon NIS Elements software. All imaging experiments were performed at 37°C in a humidified incubator (5% CO~2~). Fusion events for each cell were detected and quantified as sudden increases in fluorescence above the plasma membrane background as described ([@bib53]). At least 20 cells were imaged per condition in two independent experiments.

bEXOmiR design\--Initial development of bEXOmiRs was based on previous artificial shRNAs designs ([@bib7]) incorporating endogenous sequences derived from the putative exosomal microRNA hsa-miR-601. Specifically, a seven nt motif (GGAGGAG, 'EXO motif') together with a contiguous loop sequence (both derived from hsa-miR-601) were placed adjacent to a 15 nt random sequence (barcode) with perfect base complementarity, positioned at the base of the miRNA stem region ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). The resulting precursor hairpin was flanked by hsa-miR-30a context sequences. For the initial bEXOmiR test library, a custom C-script was written to design barcode sequences based upon specific rules: 40--60% GC content, minimum Hamming distance of 4 or more between any two barcodes, and absence of homopolymers (AAAA, UUUU, CCCC, etc.) and restriction enzyme cut sites used for cloning purposes. With this strategy, 2500 bEXOmiRs were designed, and two versions of each were used, one with an additional A-C mismatch added to ensure proper primary-miR processing ([@bib7]) for a total of 5000 bEXOmiRs.

To generate \~25,000 bEXOmiRs used in the MMM screen sublibrary, 15 base-pair barcodes were similarly generated with a minimum Hamming distance of four, moderate GC content (40--60%), and absence of homopolyers (GGGG, AAAA etc) and restriction sites. The first base-pair was altered to create a mismatch at the base of the hairpin to ensure proper processing (either A-C, T-C, G-A, or C-A). For subsequent sublibraries, this \~25,000 bEXOmiR set was filtered for either bEXOmiRs that failed to be detected in WT exosome samples (counts less than 10) or were detected at such high representation in WT exosomes as to interfere with sequencing depth (count \>10,000). Additional barcodes were randomly generated as above for larger libraries.

Stem-loop RT-PCR and qRT-PCR\--For bEXOmiR and endogenous miRNA detection in cellular or EV fractions, RNA was extracted from intact HEK293T or K562 cells, or isolated EVs using TRIzol, according to the manufacturer. EV RNAs (200--500 ng) were reverse transcribed into cDNA using Stem-Loop primers and SuperScript III FirstStrand Synthesis System (Life Technologies) according to a pulsed RT protocol ([@bib52]). Stem-loop RT primers are summarized in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. qRT-PCR experiments used a qPCR mix recipe: 1X Phusion HF buffer (NEB), 200 µM dNTPs, 1X SYBR green I (Invitrogen), HighFidelity DNA Polymerase (M0530S, NEB), and 100 nM each primer. The following programs were used: (98°C, 3', then 40X cycles of 98°C 15 s, 60°C 20 s, 72°C 3 s). A synthetic spike-in RT RNA ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) was added to each EV sample to control for variability in the starting material and the downstream RNA isolation step. The sequences of PCR primers are summarized in [Supplementary file 3](#supp3){ref-type="supplementary-material"}. qPCR was run in a BioRad CFX96 Real-Time System. PCR amplification products were analyzed on 4% agarose gels stained with ethidium bromide. For qPCR experiments related to [Figure 7](#fig7){ref-type="fig"}, total cell RNA was reverse transcribed into cDNA using oligo(dT)20 primers and SuperScript III FirstStrand Synthesis System (Life Technologies). qPCR was performed using iTaq Universal SYBR Green Supermix (BioRad) using gene-specific primers ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) and run in a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific). Transcript levels relative to HPRT1 were calculated using the ∆Ct method.

RNase protection assay\--K562 cells expressing bEXOmiRs were grown for 24 hr in RPMI and EVs were isolated from conditioned media. EVs were then treated with RNase A (10 µg/ml in PBS)±Triton X-100 (0.25%), or with PBS alone, for 30 min at room temperature. RNase inhibitor (150 U/ml, Thermo Fisher Scientific) was then added and EV-RNA isolated with TRIzol reagent (Life Technologies).

Construction of sgRNA-bEXOmiR plasmid libraries\--Oligonucleotides encoding sgRNAs ([@bib31]) coupled to individual bEXOmiRs were synthesized as pooled libraries (Agilent). BlpI and EcoRI restriction sites were introduced between sgRNA and bEXOmiR sequences. Focused sublibraries were PCR-amplified with primer sequences common to each sublibrary, digested with BstXI and MfeI enzymes, ligated into BstXI/EcoRI-digested pMCB306 vector, and transformed into electro-competent cells (Lucigen). Plasmid DNA was isolated using a QIAGEN kit. Pooled plasmids were then digested with BlpI and EcoRI, and an expression cassette encoding a puromycin-resistance gene and a GFP-ORF separated by a T2A sequence under EF-1 alpha promoter, cut with the same restriction enzyme pair, was inserted between sgRNA and bEXOmiR sequences. This generated nine focused sublibraries (*48,* [Supplementary file 4](#supp4){ref-type="supplementary-material"}), which together contained \~210,000 elements targeting \~20,000 genes with \~13,000 non-targeting and safe-targeting controls ([@bib31]); 10 sgRNA per gene, each sgRNA associated to a unique bEXOmiR).

Lentivirus production and cell infection\--Lentivirus production and infection were performed as described ([@bib21]). Briefly, HEK293T cells were co-transfected with bEXOmiR libraries or individual sgRNA vectors and third generation packaging plasmids (pVSV-G, pMDL, pRSV) using polyethylenimine. Lentivirus was harvested after 48 h-72 h and filtered through a 0.45 μm filter (Millipore). A Spinfection method was used to deliver sgRNA-bEXOmiR lentiviral plasmid sublibraries into K562 cells. Briefly, K562 cells were re-suspended in lentiviral supernatant supplemented with 8 µg/ml polybrene, distributed into 6-well plates, and centrifuged for 2 hr at 1000 × *g*, 33°C. Lentiviral supernatant was removed and cells were grown in fresh RPMI. After 48 hr recovery, 1.75 µg/ml of puromycin was added to select the cells for stable integration of the virus. Selection was monitored by flow cytometry and puromycin was removed from the media once \>95% of the cells were GFP-positive.

CRISPR/Cas9-bEXOmiR screens in K562 cells\--For genome-wide coverage, a total of nine, focused CRISPR/Cas9 deletion screens using nine different sublibraries of sgRNA-bEXOmiR associations ([Supplementary file 4](#supp4){ref-type="supplementary-material"}) were performed. WT and Cas9-expressing K562 cells were infected at low MOI (\<1). Transduced cells were selected and expanded in puromycin-supplemented media over 5--7 days before conducting experiments at 8--10 days post-infection. Initially, we performed two independent pilot screens focused on membrane trafficking, mitochondrial and motility genes (MMM screen). Subsequent screens were conducted in duplicate to further minimize technical variation observed in previous screens. Screens were started at 10,000--15,000 fold sublibrary coverage (elements per ml of cell culture) to ensure maximal bEXOmiR representation in EVs but also to minimize variability due to downstream loss of barcodes during RNA isolation and fractionation. Isolation of EVs was performed 48 hr later using protocol P2 ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Cellular fractions with at least 1000-fold sublibrary coverage were collected at the start (0 hr) and end (48 hr) of each screen.

bEXOmiR isolation and purification from screen EV RNA\--Total RNA was extracted from each EV sample using TRIzol reagent (Life Technologies), as described ([@bib24]). The resulting RNA pellet was re-suspended in nuclease-free water and equal amount of 2x RNA loading dye was added (90% formamide, 50 mM HEPES, bromophenol blue, xylene cyanide). Fractionation of total RNA was carried out on denaturating polyacrylamide gels containing 7% urea/15% acrylamide in Tris-borate-EDTA buffer (TBE). Custom 21 and 24 bp single-stranded RNA markers were used to indicate approximate miRNA migration on a gel from which gel band excision was monitored by UV shadowing. miRNAs were then gel-purified, reconstituted in nuclease-free water, and stored in −80 ˚C.

Small RNA library preparation and deep sequencing\--bEXOmiR sequencing libraries from isolated EV miRNA was prepared using a modified protocol from TruSeq Small RNA Library Preparation Kit (Illumina). For each library,\~1 µg of fractionated small RNA was ligated first to a 3'-adapter and then to 5'-adapter, followed by reverse transcription with custom primer ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) containing a fragment complementary to the EXO motif in bEXOmiRs (to specifically enrich for bEXOmiRs in the final sequencing library). Resulting cDNA was then uniquely indexed by PCR to generate the final sequencing library. Initial sequencing trials showed some rRNA contaminant fragments (specially 45S5) that were predominant in our sequencing data, which compromised sequencing depth. To remove rRNA 45S5, a specific hairpin oligo blocker ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) containing a sequence complementary to the predominant rRNA fragment was incubated after ligation of the 3' adapter to the miRNA ([@bib38]). This oligo blocked subsequent ligation of the 5' adapter to the contaminant rRNA fragment, thus excluding it from later steps. After PCR amplification, indexed samples were separated on a 4.5% low melting point agarose gel and products corresponding to 140 bp were purified using a MinElute PCR Purification Kit (Qiagen). RNA concentration was determined by Qubit fluorometer (Thermo Fisher Scientific). Pooled libraries were denatured with NaOH and diluted to 2.3 pM according to the Illumina protocol, and sequenced using a NextSeq 500/550 High Output v2 kit on NextSeq 500 system (Illumina).

Sequencing data analysis\--Sequencing of sgRNAs from DNA was trimmed and aligned using Bowtie version 1.1.2 with zero mismatches tolerated ([@bib30]). All counts from multi-mapping reads were used. For sequencing of barcodes from RNA, reads were trimmed to 14 base-pairs and aligned to the libraries using Bowtie version 1.1.2 with two mismatches tolerated and all multi-mapping reads used. [Supplementary file 5](#supp5){ref-type="supplementary-material"} and [6](#supp6){ref-type="supplementary-material"} contain bEXOmiR and sgRNA sequencing counts derived from each duplicated screen. Gene-level effects and an associated log-likelihood ratio (confidence score) were then calculated with casTLE as previously described ([@bib30]). For each gene, casTLE combines measurements from 10 different bEXOmiRs (associated with the sgRNAs targeting each gene) and gives an effect size estimate for the gene perturbation (gene K.O.) as well as a p-value associated with that effect. casTLE estimates the maximum possible phenotype such that targeting elements are most likely to be found between this phenotype and zero. Additionally, casTLE allows data from multiple screen types or from replicates of the same screen type to be compared and combined by finding a single effect size consistent with all data ([@bib30]). Briefly, low count (\<10) bEXOmiRs were filtered, and a median-normalized log count ratio was calculated for each barcode. Distributions of barcode enrichments corresponding to each gene were compared to the distribution of nontargeting and safe-targeting sgRNAs. P-values were then calculated by permuting bEXOmiRs corresponding to targeting sgRNAs. Code is available at <https://bitbucket.org/dmorgens/castle> (Copy archived at <https://github.com/elifesciences-publications/dmorgens-castle>).

Nanostring profiling was performed with the nCounter Human v3 microRNA expression assay. Control, SMPD3 and ARHGEF18 CRISPR-KO K562 polyclonal cell lines were seeded at 2.5 × 10^5^ cells/ml in EV-free RPMI medium and grown for 48 hr before EV isolation. RNA from cellular and exosomal fractions was extracted using Trizol as described ([@bib24]). EV RNA was resuspended in 4 µL H~2~O and 3 µL (\~300 ng) from each sample were used in the assay; 200 ng cellular RNA was used. RNA integrity was confirmed by Bioanalyzer before conducting the assay. Around 20 amol of synthetic spike-in RNA oligo (ath-miR-159a, see [Supplementary file 3](#supp3){ref-type="supplementary-material"}) was added to each EV sample prior to RNA extraction and used as a normalization factor in downstream EV miRNA data analysis. Raw read data from the nCounter microRNA assay were analyzed as described in the nCounter Expression Data Analysis Guide (NanoString Technologies). Data normalization for cellular miRs was perfomed using the geometric mean of the top 100 expressed miRNAs. Only miRs that passed signal-to-noise cut-off values and that were consistently detected in either cellular or EV fractions (274 and 74 miRNAs, respectively) throughout all samples, were included in the analysis and plotted using R software. Normalized miRNA counts ([Supplementary file 7](#supp7){ref-type="supplementary-material"}) from SMPD3 KO or ARHGEF18 KO samples were divided by control miRNA counts from independent experiments (n = 2) and plotted as percent of control miRNA abundance.

Generation of CRISPR-KO cell lines for validation experiments\--Polyclonal, CRISPR-KO cell lines were generated by transducing K562 stably expressing SFFV-Cas9-BFP with Lentiviral vectors encoding hit-targeting sgRNAs; at least two different sgRNAs per hit were tested. Cultures were incubated for at least 7--10 d with the sgRNAs to ensure adequate depletion of target-protein levels before conducting experiments. TIDE analysis (<https://tide.nki.nl/>) was performed to assess CRISPR deletions. Briefly, genomic DNA was extracted from cells using a QIAamp DNA mini kit (Qiagen). A 500--700 bp region containing the sgRNA cut site was amplified by PCR using GoTaq Polymerase (Promega). PCR amplification products were separated on a 0.75% TAE-agarose gel, from which amplicon bands were excised, and DNA was purified from the gel slice using a QIAquick Gel Extraction kit (Qiagen). Sanger sequencing of PCR products followed by trace decomposition analysis with TIDE software (<https://tide.nki.nl/>) was used to determine indel frequency in CRISPR-KO cell lines compared with control cells expressing a control sgRNA (targeting a genomic safe-harbor region). For validation experiments, sgRNA-expressing cell lines that showed higher degree of knockout efficiency as determined by either TIDE and/or immunoblot analysis were used ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}).

Wnt signaling\--For Wnt3a stimulation, K562 cells were starved overnight in serum-free conditions. The next day, the medium was replaced with fresh EV-free RPMI supplemented with 100 ng/ml recombinant Wnt3a protein (R and D Systems), or Wnt3a combined with 200 ng/ml recombinant DKK1 protein (R and D Systems) and EVs were collected 24 hr later. The GSK3 specific inhibitor, CHIR99021 (Selleckchem) and LiCl were used at 10 µM and 10 mM, respectively for 24 hr before collection of EVs from the medium. Quantitation of immunoblots from each of these conditions was normalized to account for cell viability, as measured by flow cytometry (BD Accuri). C59 Porcupine inhibitor was the generous gift of Dr. Roel Nusse, Stanford University.

Functional Network analysis\--Top hits were collectively queried in STRING (<https://string-db.org/>) to search for gene interactions according to co-expression, experimental or curated database sources. The resulting STRING file reporting pair-wise gene interactions was imported into Cytoscape software ([@bib41]) to create a visually comprehensive functional interactome. Interactions were represented as edges whose thickness was proportional to a calculated combined score derived from STRING analysis. The final Cytoscape map was further manually curated to include additional screen hits (nodes) that despite not being reported to interact, could still be clustered in a common functional category revealed in the screen.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"Genome-wide interrogation of extracellular vesicle release using barcoded miRNAs reveals a role for Wnt signaling\" for peer review at *eLife*. Your article is being evaluated by Anna Akhmanova as the Senior Editor, a Reviewing Editor, and three reviewers.

As you will see from the reviews, the reviewers\' opinions of your study were mixed. All reviewers feel that the bEXOmiR experimental approach is clever and may hold promise for identifying EV biogenesis pathway components. However, while the reviewers acknowledge the potential trove of new information regarding EV biogenesis, they found the breadth and diversity of the \'hits\' a matter of some concern, because for most cases it is not possible to distinguish \"fundamental\" versus \"peripheral\" hits in EV biogenesis pathways. It is a fair assumption that many of the hits impact EV biogenesis and release due to general perturbations to organelle function (that is, they do not directly participate in some aspect of EV biology). The consensus view is that additional experimentation is necessary to sufficiently validate the bEXOmiR approach and the screening data, and the reviewers request that you outline additional experimentation to address this. The reviewers would be especially encouraged by experimental data regarding mechanism: what aspect of EV biogenesis is affected by loss of ARHGEF18 and/or is regulated by Wnt signaling? The reviewers felt that the Wnt signaling and ARHGEF18 follow-up work was largely confirmatory of the original screen hits but did not provide strong additional evidence for a fundamental role of these factors in EV biogenesis or regulation. The reviewers would also have liked to see some additional data that would provide insight into the origin of the bEXOmiR-containing EV vesicle (plasma membrane? endosome? another organelle?).

Reviewer \#1:

The manuscript describes the construction and validation of a genetic screening method that links specific sgRNA sequences with synthetic miRNAs that are secreted via extra-cellular vesicles (EVs). The method allows one to use deep sequencing to gauge the effects of targeted gene knockouts on EV-mediated release of miRNAs on a whole genome scale. The method was applied in replicate screens, and its effectiveness is suggested by the identification of a handful of gene products previously implicated in EV biogenesis and/or release. In addition, at least one gene, ARHGEF18, was shown to be required for EV-mediated release of endogenous miRNAs.

I find the method to be a clever implementation of miRNA and sgRNA processing pathways to link genetics with phenotype. The most important question is, does it work? The identification of gene products previously identified as required for EV release suggests that it does. The approach did, however, require the authors to tackle a few technical bugs (e.g., DNA sequencing, effects of different sgRNA-barcode combinations, etc.) and it is not clear if further, unknown biases (if any) impact the utility of the method as a general method for evaluating the genetics of EV biogenesis. A large number of genes not previously implicated in EV biology are asserted to play roles in EV biogenesis. At this stage, it is unclear if any of the \'new\' hits play a direct role in EV cargo sorting, EV biogenesis, or EV release. As with most screens, the ultimate utility of the data will require substantial amount of follow-up work and will not be known for years to come.

*Reviewer \#2:*

In this manuscript Lu and colleagues perform a genome wide screen to get insights into the biogenesis and regulation of Extracellular Vesicle release.

For this purpose, the authors set up an elegant system based on the generation of barcoded miRNAs that depict a sequence that has been previously shown to target miRNAs to multivesicular endosomes of T lymphocytes and in particular to their intralumenal vesicles (called exosomes once they are secreted). These findings from the group of Sanchez Madrid are largely exploited here (and would deserve better acknowledgement).

The barcoded miRNAs are then used as reporters of EV release which is followed by a genome wide screen coupled with CRISPR/Cas9.

The authors have performed an incredible amount of work, that certainly is a very interesting set up.

There are several concerns with the manuscript, interpretation of results and the claims. Finally, one is a little left with the question on how such approach can really answer fundamental questions and pinpoint general or particular/specific machineries required for EV biogenesis and release.

Essential revisions:

1\) EVs comprise very different types of vesicles that are either endosome derived (so called exosomes) and plasma membrane derived. One important issue in the field is the possibility in the future to ascribe functions to the different subpopulations. Several studies have described and reported distinct machineries for the biogenesis and release of exosomes and microvesicles that can be cell type and cargo specific (summarized in different recent reviews from different authors). Therefore, it is unclear what is the approach that is here developed bringing to the complexity that has been observed and described for the very different systems.

2\) It is unclear from the claims in the manuscript and from the experiments done if one is trying to get hints on the biogenesis and release of endosome-derived exosomes or plasma membrane derived vesicles. It would certainly be important for the general audience to be clearer on this issue that is a real concern.

With this in mind, the characterization made, that is far from being very extensive, would seem to indicate that the authors maybe rather focus on endosome derived exosomes.

This point should be consolidated better with additional proteins tested by Western blot, CD63, Tsg101. For example, CD63 should rather be used for the immunofluorescence experiments presented. Lamp1, if present in late endosomes, is much more enriched in lysosomes. The experiments presented in Figure 1 and Figure 6 are difficult then to interpret.

Lamp1 is far from being the best \"exosome\" marker as in most cells Lamp1 is on the limiting membrane of the organelle and it is Lamp2 that is rather on the intraluminal vesicles. Therefore, it would be important to control whether in the cells under study Lamp1 is targeted to the intraluminal vesicles (or even if this is a consequence of the barcoded miRNAs?)

3\) Following point 2, electron microscopy combined with extra immunofluorescence imaging would be more then appropriate and required to be sure, even to set background for the all findings, that the barcoded miRNAs, once expressed are not impacting in cell/organelle morphology and/or if they are targeted to the right place. This could also help understanding the effects of Rab27A which in most cells where it is expressed (not all cells express the \"a\" isoform) is present in Golgi TGN. Rab27a is localized to Lysosome Related organelles only in specialized cells. Therefore, is Rab27a in these manipulated cells recruited to multivesicular endosomes that may specialize after introduction of the barcoded miRs? For example, this is the case in HeLa cells expressing MHC Class II and all associated molecules for antigen presentation (Ostrowski et al., 2010). The sequence used has been described to my knowledge only in T cells, is it really driving the miRs to the right place in very different cells? In conclusion extra controls would support part of the claims. This would then help understanding what subpopulation of EVs is targeted in the study.

4\) I would be more careful generalizing the concept based on the two cell lines used in this study although both express wnt.

5\) The manuscript describes the involvement of Wnt signaling in the regulation of « EV biogenesis ». For me it is unclear what is really the mechanism of Wnt action: is it on the biogenesis per se or on the release/secretion step which are different parts of the pathway? It could be only on the release but whether there are biogenetic functions remains unclear. Are vesicles still formed? Is the cargo still loaded on vesicles? One has pretty much the tendency to put together biogenesis/release but the mechanisms involved in the generation and then in the release are very distinct. The manuscript should be clear on this point.

6\) In subsection "Wnt signaling in EV biology" the authors test the effect of Wnt3a on EV release and show a decrease (is it on biogenesis or the release? by which mechanism?). This appears different from what was previously described in other cells such as microglia (Hooper et al., 2012), where Wnt3a induces exosome release, and inhibition of GSK3 does not altered exosome secretion, indicating that exosome release occurs through a GSK3-independent mechanism. Such discrepancy is not described, and the paper not quoted if I am not wrong.

7\) In concern to the effects of YKT6 that has been described by the group of Boutros as required for exosome-dependent Wnt release in *Drosophila* wing disc and cells and Hela cells, the paper of Gross et al., 2012 is not quoted.

8\) In Figure 1---figure supplement 1B and in the legend there is a discrepancy: in the figure it is 12.200g and in the legend 10.000 g and the time of not indicated in the figure.

9\) Figure 5B in the text there is a reference to cells versus EVs (subsection "A CRISPR/Cas9 screen using bEXOmiRs") though unclear in the Figure.

In conclusion, it is an elegant set up that deserves attention but certainly additional controls. At this point in my opinion it is more the set-up of a new method that maybe will set the stage for more meaningful experiments in the future. This may help to better target potential mechanisms and therefore understand the crosstalks and pathways influencing EV (rather subpopulations of EVs) biogenesis and release which should be separated as this are very different processes.

Reviewer \#3:

In this manuscript, Albert Lu and colleagues, have designed a screen to identify regulators of the secretion of extracellular vesicles (EV). They have used a clever design by combining bar-coding of the EV with a single guide RNA to target genes using the Cas9 enzyme. Bar-coding is achieved using custom-designed miRNAs, the bEXOmiR.

The authors used a pool screen format where an excess of cells is transfected with a complex library of viruses. Next generation sequencing then quantifies the abundance of specific miRNA in the supernatant of the pool of cells. Because each gene-specific guide RNA is combined with a specific bEXOmiR, inference can be drawn from the levels of a bEXOmiR in the supernatant.

This is an elegant study that provides a valuable resource for researchers interested in EV. It also provides a proof of concept that such bar-coding of EV is feasible. Finally, it demonstrates elegantly that Wnt signaling is involved in regulating EV secretion.

In such pooled screens, the normalisation steps are really key to avoid mis-interpreting the data. In this case, Lu and colleagues have normalised first the bEXOmiR count to a cell line devoid of the nuclease Cas9. This should exclude any effect that the bEXOmiR barcode could have on packaging into EV or the effect the miRNAs could have on gene expression. The authors show convincingly that this is the case.

The next concern would be that the CRISPR targeted gene would affect the synthesis of the bar-coded miRNA instead of packaging and export in EV. These are admittedly two very different processes and it would be advantageous to distinguish them.

As far as I could see, the authors did not use the comparison extra/intra cellular levels of bEXOmiR to sort their hits. It would be interesting to sort the hits based on whether there is an individual correlation between intracellular and extracellular amount of bEXOmiR upon gene knockout. This should be the case for the hits proposed to be involved in \"miRNA processing and trafficking\" (proposal based on previous annotations) (Figure 4). In theory it could help sort the other hits between miRNA processing and EV biosynthesis, especially for RNA binding proteins.

The final concern with screen design would be whether some genes could affect the uptake and degradation of EV. Indeed, as this is a suspension culture, cells have in theory the capacity to affect the extracellular levels of EV also through endocytosis and degradation. A hit that would affect the membrane surface of EV and thus affect EV binding to neighbouring cells after secretion could, in theory affect the overall levels of EV without affecting their synthesis and release. I wonder if this could be an explanation for the effect of some of the extracellular proteins identified (Figure 4). I wonder if the authors can exclude this effect or control for it?

\" Unexpectedly, YKT6, which appeared as a suppressor in the initial screen (Figure 2B), was uncovered as a slight activator instead; this may be related to differences in the bEXOmiRs associated with this gene in the two separate analyses..... This discrepancy highlights the importance of orthogonal hit validation experiments.\"

It also highlights the difficulty in interpreting the significance score (-Log10(P-value) to evaluate reproducibility. I have trouble evaluating how many pairs of bEXOmiRs-sgRNA gave similar results with this metric.

It would be surprising that the YKT6 case would occur if the result found in the main screen is attributable to 3 or 4 pairs of bEXOmiR+sgRNA. I think it would help clarify the data if the authors provided a table with the result for each gene: with how many constructs gave a result and what score.

10.7554/eLife.41460.028

Author response

> As you will see from the reviews, the reviewers\' opinions of your study were mixed. All reviewers feel that the bEXOmiR experimental approach is clever and may hold promise for identifying EV biogenesis pathway components. However, while the reviewers acknowledge the potential trove of new information regarding EV biogenesis, they found the breadth and diversity of the \'hits\' a matter of some concern, because for most cases it is not possible to distinguish \"fundamental\" versus \"peripheral\" hits in EV biogenesis pathways. It is a fair assumption that many of the hits impact EV biogenesis and release due to general perturbations to organelle function (that is, they do not directly participate in some aspect of EV biology). The consensus view is that additional experimentation is necessary to sufficiently validate the bEXOmiR approach and the screening data, and the reviewers request that you outline additional experimentation to address this. The reviewers would be especially encouraged by experimental data regarding mechanism: what aspect of EV biogenesis is affected by loss of ARHGEF18 and/or is regulated by Wnt signaling? The reviewers felt that the Wnt signaling and ARHGEF18 follow-up work was largely confirmatory of the original screen hits but did not provide strong additional evidence for a fundamental role of these factors in EV biogenesis or regulation. The reviewers would also have liked to see some additional data that would provide insight into the origin of the bEXOmiR-containing EV vesicle (plasma membrane? endosome? another organelle?).

We believe that the live cell imaging shows that loss of EVs from our studied hits is due to decreased exocytosis of multivesicular endosomes -- a very important new finding. In addition, we provide a molecular explanation for how the GSK3 inhibition blocks K562 MVE release -- by decreasing Rab27 mRNA and protein levels.

> Reviewer \#1:
>
> The manuscript describes the construction and validation of a genetic screening method that links specific sgRNA sequences with synthetic miRNAs that are secreted via extra-cellular vesicles (EVs). The method allows one to use deep sequencing to gauge the effects of targeted gene knockouts on EV-mediated release of miRNAs on a whole genome scale. The method was applied in replicate screens, and its effectiveness is suggested by the identification of a handful of gene products previously implicated in EV biogenesis and/or release. In addition, at least one gene, ARHGEF18, was shown to be required for EV-mediated release of endogenous miRNAs.
>
> I find the method to be a clever implementation of miRNA and sgRNA processing pathways to link genetics with phenotype. The most important question is, does it work?

Thank you.

> The identification of gene products previously identified as required for EV release suggests that it does.

We agree.

> The approach did, however, require the authors to tackle a few technical bugs (eg, DNA sequencing, effects of different sgRNA-barcode combinations, etc) and it is not clear if further, unknown biases (if any) impact the utility of the method as a general method for evaluating the genetics of EV biogenesis.

We are very honest about limitations of the screen and explored some of them -- it is genome wide, but we do not claim that it is a saturation screen.

> A large number of genes not previously implicated in EV biology are asserted to play roles in EV biogenesis. At this stage, it is unclear if any of the \'new\' hits play a direct role in EV cargo sorting, EV biogenesis, or EV release.

Our live cell pHluorin-CD63 TIRF experiments strongly suggest that MVE release is the problem in characterized hit-depleted cells -- CD63-positive structures don't appear to change, but their probability of release does.

> As with most screens, the ultimate utility of the data will require substantial amount of follow-up work and will not be known for years to come.

We agree -- thanks for acknowledging this.

> Reviewer \#2:
>
> In this manuscript Lu and colleagues perform a genome wide screen to get insights into the biogenesis and regulation of Extracellular Vesicle release.
>
> For this purpose, the authors set up an elegant system based on the generation of barcoded miRNAs that depict a sequence that has been previously shown to target miRNAs to multivesicular endosomes of T lymphocytes and in particular to their intralumenal vesicles (called exosomes once they are secreted). These findings from the group of Sanchez Madrid are largely exploited here (and would deserve better acknowledgement).

We did cite their paper and added additional acknowledgement.

> The barcoded miRNAs are then used as reporters of EV release which is followed by a genome wide screen coupled with CRISPR/Cas9.
>
> The authors have performed an incredible amount of work, that certainly is a very interesting set up.
>
> There are several concerns with the manuscript, interpretation of results and the claims. Finally, one is a little left with the question on how such approach can really answer fundamental questions and pinpoint general or particular/specific machineries required for EV biogenesis and release.
>
> Essential revisions:
>
> 1\) EVs comprise very different types of vesicles that are either endosome derived (so called exosomes) and plasma membrane derived. One important issue in the field is the possibility in the future to ascribe functions to the different subpopulations. Several studies have described and reported distinct machineries for the biogenesis and release of exosomes and microvesicles that can be cell type and cargo specific (summarized in different recent reviews from different authors). Therefore, it is unclear what is the approach that is here developed bringing to the complexity that has been observed and described for the very different systems.

We have added new NTA Nanoparticle tracking which shows that our vesicles are rather uniform and small in size and more importantly, we added live cell imaging that now shows that our hits are really important for MVE exocytosis. These are very major new additions that tell us about the pathway involved, greatly increasing the significance of our story.

> 2\) It is unclear from the claims in the manuscript and from the experiments done if one is trying to get hints on the biogenesis and release of endosome-derived exosomes or plasma membrane derived vesicles. It would certainly be important for the general audience to be clearer on this issue that is a real concern.

See above -- our new data address this very well.

> With this in mind, the characterization made, that is far from being very extensive, would seem to indicate that the authors maybe rather focus on endosome derived exosomes. This point should be consolidated better with additional proteins tested by Western blot, CD63, Tsg101. For example, CD63 should rather be used for the immunofluorescence experiments presented. Lamp1, if present in late endosomes, is much more enriched in lysosomes. The experiments presented in Figure 1 and Figure 6 are difficult then to interpret.

We have used CD63 is our exocytosis marker and we also now include CD63 IF (new Figure 1---figure supplement 2, Figure 5 and Figure 5---figure supplement 3.

> Lamp1 is far from being the best \"exosome\" marker as in most cells Lamp1 is on the limiting membrane of the organelle and it is Lamp2 that is rather on the intraluminal vesicles. Therefore, it would be important to control whether in the cells under study Lamp1 is targeted to the intraluminal vesicles (or even if this is a consequence of the barcoded miRNAs?)

We added additional markers thus this is not needed at this stage (see above).

> 3\) Following point 2, electron microscopy combined with extra immunofluorescence imaging would be more then appropriate and required to be sure, even to set background for the all findings, that the barcoded miRNAs, once expressed are not impacting in cell/organelle morphology and/or if they are targeted to the right place. This could also help understanding the effects of Rab27A which in most cells where it is expressed (not all cells express the \"a\" isoform) is present in Golgi TGN. Rab27a is localized to Lysosome Related organelles only in specialized cells. Therefore, is Rab27a in these manipulated cells recruited to multivesicular endosomes that may specialize after introduction of the barcoded miRs? For example, this is the case in HeLa cells expressing MHC Class II and all associated molecules for antigen presentation (Ostrowski et al., 2010). The sequence used has been described to my knowledge only in T cells, is it really driving the miRs to the right place in very different cells? In conclusion extra controls would support part of the claims. This would then help understanding what subpopulation of EVs is targeted in the study.

The live cell imaging really supports the idea that MVE release is what is impacted here. The NTA shows it is small vesicles. We have added more IF to show that the bEXOmiRs don't change CD63compartment morphology (new Figure 1---figure supplement 2). As reported by others and shown here, Rab27 depletion decreases MVE exocytosis and EV recovery.

> 4\) I would be more careful generalizing the concept based on the two cell lines used in this study although both express wnt.

We have modified the text as requested and toned down the Title.

> 5\) The manuscript describes the involvement of Wnt signaling in the regulation of « EV biogenesis ». For me it is unclear what is really the mechanism of Wnt action: is it on the biogenesis per se or on the release/secretion step which are different parts of the pathway? It could be only on the release but whether there are biogenetic functions remains unclear. Are vesicles still formed? Is the cargo still loaded on vesicles? One has pretty much the tendency to put together biogenesis/release but the mechanisms involved in the generation and then in the release are very distinct. The manuscript should be clear on this point.

Again, we now use live cell imaging and show that loss of Rab27 blocks EV exocytosis and importantly, that GSK3 inhibition decreases Rab27 mRNA and protein. Thus, the pathway is now much clearer.

> 6\) In subsection "Wnt signaling in EV biology" the authors test the effect of Wnt3a on EV release and show a decrease (is it on biogenesis or the release? by which mechanism?). This appears different from what was previously described in other cells such as microglia (Hooper et al., 2012), where Wnt3a induces exosome release, and inhibition of GSK3 does not altered exosome secretion, indicating that exosome release occurs through a GSK3-independent mechanism. Such discrepancy is not described, and the paper not quoted if I am not wrong.

We confirm here that different cells have different responses to GSK3 inhibition and have included this reference.

> 7\) In concern to the effects of YKT6 that has been described by the group of Boutros as required for exosome-dependent Wnt release in Drosophila wing disc and cells and Hela cells, the paper of Gross et al., 2012 is not quoted.

We apologize and added this reference.

> 8\) In Figure 1---figure supplement 1B and in the legend there is a discrepancy: in the figure it is 12.200g and in the legend 10.000 g and the time of not indicated in the figure.

Thank you for detecting that error-now corrected.

> 9\) Figure 5B in the text there is a reference to cells versus EVs (subsection "A CRISPR/Cas9 screen using bEXOmiRs") though unclear in the Figure.

We fixed this figure -- they are now labeled more clearly at the top.

> In conclusion, it is an elegant set up that deserves attention but certainly additional controls. At this point in my opinion it is more the set-up of a new method that maybe will set the stage for more meaningful experiments in the future. This may help to better target potential mechanisms and therefore understand the crosstalks and pathways influencing EV (rather subpopulations of EVs) biogenesis and release which should be separated as this are very different processes.

We thank the reviewer and wish to remind all the reviewers that this was submitted as a Resource.

> Reviewer \#3:
>
> In this manuscript, Albert Lu and colleagues, have designed a screen to identify regulators of the secretion of extracellular vesicles (EV). They have used a clever design by combining bar-coding of the EV with a single guide RNA to target genes using the Cas9 enzyme. Bar-coding is achieved using custom-designed miRNAs, the bEXOmiR.
>
> The authors used a pool screen format where an excess of cells is transfected with a complex library of viruses. Next generation sequencing then quantifies the abundance of specific miRNA in the supernatant of the pool of cells. Because each gene-specific guide RNA is combined with a specific bEXOmiR, inference can be drawn from the levels of a bEXOmiR in the supernatant.
>
> This is an elegant study that provides a valuable resource for researchers interested in EV. It also provides a proof of concept that such bar-coding of EV is feasible. Finally, it demonstrates elegantly that Wnt signaling is involved in regulating EV secretion.

Thank you.

> In such pooled screens, the normalisation steps are really key to avoid mis-interpreting the data. In this case, Lu and colleagues have normalised first the bEXOmiR count to a cell line devoid of the nuclease Cas9. This should exclude any effect that the bEXOmiR barcode could have on packaging into EV or the effect the miRNAs could have on gene expression. The authors show convincingly that this is the case.

Thank you.

> The next concern would be that the CRISPR targeted gene would affect the synthesis of the bar-coded miRNA instead of packaging and export in EV. These are admittedly two very different processes and it would be advantageous to distinguish them.
>
> As far as I could see, the authors did not use the comparison extra/intra cellular levels of bEXOmiR to sort their hits. It would be interesting to sort the hits based on whether there is an individual correlation between intracellular and extracellular amount of bEXOmiR upon gene knockout. This should be the case for the hits proposed to be involved in \"miRNA processing and trafficking\" (proposal based on previous annotations) (Figure 4). In theory it could help sort the other hits between miRNA processing and EV biosynthesis, especially for RNA binding proteins.

We have not sorted our hits according to packaging efficiency and note this in the revised text. We did address this in Figure 5 for the Nanostring experiment where specific miRNA levels only change in the EV but not cellular fractions. Orthogonal validation is thus important to ensure it was not a bEXOmiR synthesis issue - monitoring the release of endogenous miRNAs instead of bEXOmiRs and creating CRISPR cell lines that show the same phenotype for specific hits without any bEXOmiRs. By using 10 different bEXOmiRs for every gene, we tried to minimize any biosynthesis bias. In addition, we now more clearly explain Figure 3 where we show no correlation between abundance of total bEXOmiRs in cells compared with EVs. We also validated the roles of the hits using TIRF, confirming the use of these reporters to good end.

> The final concern with screen design would be whether some genes could affect the uptake and degradation of EV. Indeed, as this is a suspension culture, cells have in theory the capacity to affect the extracellular levels of EV also through endocytosis and degradation. A hit that would affect the membrane surface of EV and thus affect EV binding to neighbouring cells after secretion could, in theory affect the overall levels of EV without affecting their synthesis and release. I wonder if this could be an explanation for the effect of some of the extracellular proteins identified (Figure 4). I wonder if the authors can exclude this effect or control for it?

Although endocytosis of EVs by surface proteins might lead to a decrease in EV bEXOmiR abundance, we did not detect a large cluster of endocytosis genes in our screen and state this in the text.

> \" Unexpectedly, YKT6, which appeared as a suppressor in the initial screen (Figure 2B), was uncovered as a slight activator instead; this may be related to differences in the bEXOmiRs associated with this gene in the two separate analyses..... This discrepancy highlights the importance of orthogonal hit validation experiments.\"
>
> It also highlights the difficulty in interpreting the significance score (-Log10(P-value) to evaluate reproducibility. I have trouble evaluating how many pairs of bEXOmiRs-sgRNA gave similar results with this metric.

Our screen has many limitations and the CASTLE score emphasizes the outliers. Again, different bEXOmiRs have variable efficiencies as do different guides, and one would need to redo the screen with a more limited, enhanced set to have better genome-wide coverage. We have added better data on recovery of each bEXOmiR for all the hits in a new Table 7 as requested.

> It would be surprising that the YKT6 case would occur if the result found in the main screen is attributable to 3 or 4 pairs of bEXOmiR+sgRNA. I think it would help clarify the data if the authors provided a table with the result for each gene: with how many constructs gave a result and what score.

Done as requested -- usually 2-3 guide-bEXOmiR associations supported each hit. Text modified.
